Natural antimicrobial solution for wheat flour safety enhancement
Veos Pharmaceuticals introduces BioPropello, a natural antimicrobial solution designed to reduce microbial load in wheat flour during tempering. This solution targets E. coli, Salmonella sp., and Enterobacteriaceae without affecting flour quality or baking properties, ensuring safety and compliance.
Overview
Veos Pharmaceuticals presents BioPropello, an innovative natural antimicrobial solution that enhances the safety of wheat flour by significantly reducing microbial contamination. This product is specifically designed to target harmful bacteria such as Escherichia coli and Salmonella sp. during the wheat tempering process, seamlessly integrating into existing milling operations. BioPropello promises to improve microbial safety while maintaining the nutritional and baking properties of the flour, ensuring compliance with industry standards and regulatory requirements.
Technical specifications
Key Features:
- Targets and reduces microbial load by a minimum of 2-log in wheat flour
- Specifically effective against Escherichia coli, Salmonella sp., and Enterobacteriaceae
- No adverse effects on flour's baking and nutritional properties
- Compatible with existing milling processes
Implementation:
- Applied during the wheat tempering stage
- Validated through controlled experiments and field trials at multiple milling sites
- Performance measured using standard plating methods for microbial counts
- Ensures seamless integration without requiring major changes to current infrastructure
Technology readiness level
BioPropello is currently at Technology Readiness Level 4 (TRL 4), indicating that it has been validated in laboratory settings and small-scale field trials. Future validation will focus on its efficacy in large-scale commercial operations, ensuring its readiness for widespread industry adoption.
About Veos Pharmaceuticals
Veos Pharmaceuticals is a Madrid-based biotechnology company that develops and commercializes science-backed solutions across human health, agriculture, and environmental sustainability. Founded in 2023, the company operates as a vertically integrated entity, maintaining direct control over research, formulation, regulatory compliance, and distribution across Europe and North America. Its platform-based innovation model is built on scientific rigor and commercial discipline, resulting in a portfolio of more than 40 commercial products. By combining internal R&D with selective in-licensing and strategic partnerships, Veos translates validated research into scalable, real-world applications. The firm distinguishes itself through its focus on profitability, which it has maintained since 2024, and its commitment to manufacturing standards, leveraging European facilities to ensure quality and regulatory adherence.
The company's work provides critical value to diverse stakeholders, including patients, clinicians, growers, and industrial partners. Its human health platform delivers pharmaceutical and nutraceutical products targeting areas such as ophthalmology and muscle health, while its agricultural and environmental platforms focus on enhancing crop resilience, water treatment, and material recovery. Through its direct-to-consumer and business-to-business channels, Veos addresses specific market needs with evidence-based technologies. The company’s growth is supported by a senior leadership team with extensive expertise in pharmaceutical operations and biotechnology, and it actively collaborates with research institutions and global distributors to expand the deployment and impact of its technologies.
Inquire about this partnering listing
Industry applications
delivered to your inbox.